Skip to main content
SpringerLink
Log in

Therapies Targeted at Preserving Microvascular Integrity and Preventing Reperfusion Injury

  • Chapter
  • First Online:
Primary Angioplasty in Acute Myocardial Infarction

Part of the book series: Contemporary Cardiology ((CONCARD))

  • 808 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kloner RA, Ganote CE, Jennings RB. The “no-reflow” phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 1974 Dec; 54(6): 1496–508.

    Article  PubMed  CAS  Google Scholar 

  2. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med. 1985 Apr 4; 312(14): 932–6.

    Google Scholar 

  3. Anderson JL, Karagounis LA, Califf RM. Metaanalysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction. Am J Cardiol 1996 Jul 1; 78(1): 1–8.

    Article  PubMed  CAS  Google Scholar 

  4. Gibson CM, Cannon CP, Murphy SA, Ryan KA, Mesley R, Marble SJ, McCabe CH, Van De Werf F, Braunwald E. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000 Jan 18; 101(2): 125–30

    PubMed  CAS  Google Scholar 

  5. Morishima I, Sone T, Mokuno S, Taga S, Shiauchi A, Oki Y, et al. Clinical Significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous coronary angioplasty. Am Heart J 1995; 239–43.

    Google Scholar 

  6. Costantini CO, Stone GW, Mehran R, et al. Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. J Am Coll Cardiol 2004; 44: 305–12.

    Article  PubMed  Google Scholar 

  7. Berger PB, Ellis SG, Holmes DR Jr, Granger CB, Criger DA, Betriu A, Topol EJ, Califf RM. Relationship Between Delay in Performing Direct Coronary Angioplasty and Early Clinical Outcome in Patients With Acute Myocardial Infarction. Results From the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (GUSTO-IIb) Trial. Circulation. 1999 Jul 6; 100(1): 14–20.

    PubMed  CAS  Google Scholar 

  8. Forman MB, Puett DW, Virmani R. Endothelial and myocardial injury during ischemia and reperfusion: pathogenesis and therapeutic implications. J Am Coll Cardiol 1989 Feb; 13(2): 450–9.

    Article  PubMed  CAS  Google Scholar 

  9. Vanden Hoek TL, Shao Z, Li C, Zak R, Schumacker PT, Becker LB. Reperfusion injury on cardiac myocytes after simulated ischemia. Am J Physiol 1996 Apr; 270(4 Pt 2): H1334–41.

    PubMed  CAS  Google Scholar 

  10. Wu KC, Kim RJ, Bluemke DA, Rochitte CE, Zerhouni EA, Becker LC, Lima JA. Quantification and time course of microvascular obstruction by contrast-enhanced echocardiography and magnetic resonance imaging following acute myocardial infarction and reperfusion. J Am Coll Cardiol 1998 Nov 15; 32(6): 1756–64.

    Article  PubMed  CAS  Google Scholar 

  11. Porto I, Burzotta F, Brancati M, Trani C, Lombardo A, Romagnoli E, Niccoli G, Natale L, Bonomo L, Crea F. Relation of myocardial blush grade to microvascular perfusion and myocardial infarct size after primary or rescue percutaneous coronary intervention. Am J Cardiol. 2007 Jun 15; 99(12): 1671–3.

    Article  PubMed  Google Scholar 

  12. Korosoglou G, Haars A, Michael G, Erbacher M, Hardt S, Giannitsis E, Kurz K, Franz-Josef N, Dickhaus H, Katus HA, Kuecherer H. Quantitative evaluation of myocardial blush to assess tissue level reperfusion in patients with acute ST-elevation myocardial infarction: incremental prognostic value compared with visual assessment. Am Heart J. 2007 Apr; 153(4): 612–20.

    Google Scholar 

  13. Destro G, Marino P, Barbieri E, Zorzi A, Brighetti G, Maines M, Carletti M, Zardini P. Postinfarctional remodeling: increased dye intensity in the myocardial risk area after angioplasty of infarct-related coronary artery is associated with reduction of ventricular volumes. J Am Coll Cardiol 2001 Apr; 37(5): 1239–45.

    Article  PubMed  CAS  Google Scholar 

  14. Morishima I, et al. JACC 2000.

    Google Scholar 

  15. Rochitte CE, Lima JA, Bluemke DA, Reeder SB, McVeigh ER, Furuta T, Becker LC, Melin JA. Magnitude and time course of microvascular obstruction and tissue injury after acute myocardial infarction. Circulation 1998 Sep 8; 98(10): 1006–14.

    Google Scholar 

  16. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, McCabe CH, Raymond L, Fortin T, Poole WK, Braunwald E. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996 Mar 1; 93(5): 879–88.

    Google Scholar 

  17. Arnoud W.J. van’t Hof, MD, Aylee Liem, MD, Harry Suryapranata, MD, Jan C.A. Hoorntje, MD, Menko-Jan de Boer, MD, Felix Zijlstra, MD,; on behalf of the Zwolle Myocardial Infarction Study Group. Angiographic Assessment of Myocardial Reperfusion in Patients Treated With Primary Angioplasty for Acute Myocardial Infarction: Myocardial Blush Grade. Circulation. 1998; 97: 2302–2306.

    Google Scholar 

  18. Gibson CM, Cannon CP, Murphy SA, Ryan KA, Mesley R, Marble SJ, McCabe CH, Van De Werf F, Braunwald E. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000 Jan 18; 101(2): 125–30.

    Google Scholar 

  19. Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: a review of mechanisms and therapies. Eur Heart J 2001 May; 22(9): 729–39.

    Google Scholar 

  20. Abbo KM, Dooris M, Glazier S, O'Neill WW, Byrd D, Grines CL, Safian RD. Features and outcome of no-reflow after percutaneous coronary intervention.. Am J Cardiol 1995 Apr 15; 75(12): 778–82.

    Google Scholar 

  21. Piana RN, Paik GY, Moscucci M, Cohen DJ, Gibson CM, Kugelmass AD, Carrozza JP Jr, Kuntz RE, Baim DS. Incidence and treatment of ‘no-reflow’ after percutaneous coronary intervention. Circulation 1994 Jun; 89(6): 2514–8.

    Google Scholar 

  22. Mehta RH, Harjai KJ, Boura J, Cox D, Stone GW, O'Neill W, Grines CL; Primary Angioplasty in Myocardial Infarction (PAMI) Investigators. Prognostic significance of transient no-reflow during primary percutaneous coronary intervention for ST-elevation acute myocardial infarction. Am J Cardiol. 2003 Dec 15; 92(12): 1445–7.

    Google Scholar 

  23. Brosh D, Assali A, Mager A, Porter A, Hasdai D, Teplitsky I, Rechavia E, Fuchs S, Battler A, Kornowski R. Effect of No-Reflow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction on Six-Month Mortality. The American Journal of Cardiology, 99(4): 442–445.

    Google Scholar 

  24. Katayama T, Kubo N, Takagi Y, Funayama H, Ikeda N, Ishida T, Hirahara T, Sugawara Y, Yasu T, Kawakami M, Saito M. Relation of atherothrombosis burden and volume detected by intravascular ultrasound to angiographic no-reflow phenomenon during stent implantation in patients with acute myocardial infarction. Am J Cardiol. 2006 Feb 1; 97(3): 301–4.

    Google Scholar 

  25. Yip HK, Chen MC, Chang HW, Hang CL, Hsieh YK, Fang CY, Wu CJ. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon. Chest. 2002 Oct; 122(4): 1322–32.

    Google Scholar 

  26. Maekawa Y, Asakura Y, Anzai T, Ishikawa S, Okabe T, Yoshikawa T, Ogawa S. Relation of stent overexpansion to the angiographic no-reflow phenomenon in intravascular ultrasound-guided stent implantation for acute myocardial infarction. Heart Vessels. 2005 Feb; 20(1): 13–8.

    Google Scholar 

  27. Prasad A, Stone GW, Stuckey TD, Costantini CO, Zimetbaum PJ, McLaughlin M, Mehran R, Garcia E, Tcheng JE, Cox DA, Grines CL, Lansky AJ, Gersh BJ. Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction. J Am Coll Cardiol. 2005 Feb 15; 45(4): 508–14.

    Google Scholar 

  28. Iwakura K, Ito H, Kawano S, Okamura A, Kurotobi T, Date M, Inoue K, Fujii K. Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur Heart J. 2006 Mar; 27(5): 534–9.

    Google Scholar 

  29. Zhao JL, Yang YJ, Zhang YH, Pei WD, Sun YH, Chen JL, Gao RL. Chronic pretreatment of ACEI reduces no-reflow in patients with acute myocardial infarction treated with primary angioplasty. Clin Cardiol. 2007 Mar; 30(3): 130–4.

    Google Scholar 

  30. Rentrop KP, Blanke H, Karsch KR, Wiegand V, Kostering H, Oster H, Leitz K. Acute myocardial infarction: intracoronary application of nitroglycerin and streptokinase. Clin Cardiol 1979 Oct; 2(5): 354–63.

    Google Scholar 

  31. Linden J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 2001; 41: 775–87.

    Article  PubMed  CAS  Google Scholar 

  32. Hata K, Whittaker P, Kloner RA, Przyklenk K. Brief antecedent ischemia attenuates platelet-mediated thrombosis in damaged and stenotic canine coronary arteries: role of adenosine. Circulation 1998 Feb 24; 97(7): 692–702

    PubMed  CAS  Google Scholar 

  33. Heidland UE, Heintzen MP, Schwartzkopff B, Strauer BE. Preconditioning during percutaneous transluminal coronary angioplasty by endogenous and exogenous adenosine. Am Heart J 2000 Nov; 140(5): 813–20.

    Article  PubMed  CAS  Google Scholar 

  34. Wasir H, Bhan A, Choudhary SK, Sharma R, Chauhan S, Venugopal P. Pretreatment of human myocardium with adenosine. Eur J Cardiothorac Surg 2001 Jan; 19(1): 41–6.

    Article  PubMed  CAS  Google Scholar 

  35. Miller B, Lesnefsky E, Heyborne T, Schmidt B, Freeman K, Breckinridge S, Kelley K, Mann D, Reiter M.. Cough-cardiopulmonary resuscitation in the cardiac catheterization laboratory: hemodynamics during an episode of prolonged hypotensive ventricular tachycardia. Cathet Cardiovasc Diagn 1989 Nov; 18(3): 168–71.

    Google Scholar 

  36. Claeys MJ, Vrints CJ, Bosmans JM, Conraads VM, Snoeck JP. Aminophylline inhibits adaptation to ischaemia during angioplasty. Role of adenosine in ischaemic preconditioning. Eur Heart J 1996 Apr; 17(4): 539–44.

    Google Scholar 

  37. Schaefer S, Correa SD, Valente RJ, Laslett LJ. Blockade of adenosine receptors with aminophylline limits ischemic preconditioning in human beings. Am Heart J. 2001 Sep; 142(3): E4.

    Google Scholar 

  38. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation. 2000 May 9; 101(18): 2154–9.

    Google Scholar 

  39. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, Eisenberg PR, Bolli R, Casas AC, Molina-Viamonte V, Orlandi C, Blevins R, Gibbons RJ, Califf RM, Granger CB. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 1999 Nov 15; 34(6): 1711–20.

    Google Scholar 

  40. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW; AMISTAD-II Investigators. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol. 2005 Jun 7; 45(11): 1775–80.

    Article  PubMed  CAS  Google Scholar 

  41. S. Kopecky, R. Aviles, M.R. Bell, J.K. Lobl, D. Tipping, G. Frommell, K. Ramsey, A.E. Holland, M. Midei, A. Jain, M. Kellett and R.J. Gibbons, A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty the ADMIRE (AmP579 Delivery for Myocardial Infarction REduction) study, Am Heart J 146 (2003), pp. 146–152.

    Article  PubMed  CAS  Google Scholar 

  42. Micari A, Belcik TA, Balcells EA, Powers E, Wei K, Kaul S, Lindner JR. Improvement in microvascular reflow and reduction of infarct size with adenosine in patients undergoing primary coronary stenting. Am J Cardiol. 2005 Nov 15; 96(10): 1410–5.

    Article  PubMed  CAS  Google Scholar 

  43. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987 Jun 11–17;327(6122): 524–6.

    Google Scholar 

  44. Hillegass WB, Dean NA, Liao L, Rhinehart RG, Myers PR. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience, J Am Coll Cardiol 2001 April; 37: 1335–1343.

    Google Scholar 

  45. Airoldi F, Briguori C, Cianflone D, Cosgrave J, Stankovic G, Godino C, Carlino M, Chieffo A, Montorfano M, Mussardo M, Michev I, Colombo A, Maseri A. Frequency of slow coronary flow following successful stent implantation and effect of Nitroprusside. Am J Cardiol. 2007 Apr 1; 99(7): 916–20.

    Google Scholar 

  46. Amit G, Cafri C, Yaroslavtsev S, Fuchs S, Paltiel O, Abu-Ful A, Weinstein JM, Wolak A, Ilia R, Zahger D. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. Am Heart J. 2006 Nov; 152(5): 887.e9–14.

    Google Scholar 

  47. Hendler A, Aronovich A, Kaluski E, Zyssman I, Gurevich Y, Blatt A, Reicher M, Leitman M, Czuriga I, Vered Z, Krakover R. Optimization of myocardial perfusion after primary coronary angioplasty following an acute myocardial infarction. Beyond TIMI 3 flow. J Invasive Cardiol. 2006 Jan; 18(1): 32–6.

    PubMed  Google Scholar 

  48. Ishihara M, Sato H, Tateishi H, Kawagoe T, Shimatani Y, Kurisu S, Sakai K. Attenuation of the no-reflow phenomenon after coronary angioplasty for acute myocardial infarction with intracoronary papaverine. Am Heart J. 1996 Nov; 132(5): 959–63.

    Google Scholar 

  49. Taniyama Y, Ito H, Iwakura K, Masuyama T, Hori M, Takiuchi S, Nishikawa N, Higashino Y, Fujii K, Minamino T. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol. 1997 Nov 1; 30(5): 1193–9.

    Google Scholar 

  50. Kaplan BM, Benzuly KH, Kinn JW, Bowers TR, Tilli FV, Grines CL, O'Neill WW, Safian RD. Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn. 1996 Oct;39(2): 113–8.

    Google Scholar 

  51. Hang CL, Wang CP, Yip, HK, Yang CH, Guo GB, Wu CJ, Chen SM. Early administration of intracoronary verapamil improves myocardial perfusion during percutaneous coronary interventions for acute myocardial infarction. Chest. 2005 Oct;128(4): 2593–8.

    Article  PubMed  CAS  Google Scholar 

  52. Dose-dependent effects of intracoronary verapamil on systemic and coronary hemodynamics. Cardiovasc Drugs Ther. 2000 Dec;14(6): 651–5.

    Google Scholar 

  53. Herzog WR, Vogel RA, Schlossberg ML, Edenbaum LR, Scott HJ, Serebruany VL. Short-term low dose intracoronary diltiazem administered at the onset of reperfusion reduces myocardial infarct size. Int J Cardiol. 1997 Mar;59(1): 21–7.

    Article  PubMed  CAS  Google Scholar 

  54. Jalinous F, Mooney JA, Mooney MR. Pretreatment with Intracoronary Diltiazem Reduces Non-Q-Wave Myocardial Infarction Following Directional Atherectomy. J Invasive Cardiol. 1997 May; 9(4): 270–273.

    Google Scholar 

  55. Pizzetti G, Mailhac A, Volsi LL, Di Marco F, Lu Ch, Margonato A, et al. Beneficial effects of diltiazem during myocardial reperfusion: a randomized trial in acute myocardial infarction. Ital Heart J 2001; 2 (10): 757–765.

    PubMed  CAS  Google Scholar 

  56. Fugit MD, Rubal BJ, Donovan DJ. Effects of intracoronary nicardipine, diltiazem and verapamil on coronary blood flow. J Invasive Cardiol. 2000 Feb; 12(2): 80–5.

    Google Scholar 

  57. Huang RI, Patel P, Walinsky P, Fischman DL, Ogilby JD, Awar M, Frankil C, Savage MP. Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention. Catheter Cardiovasc Interv. 2006 Nov; 68(5): 671–6.

    Google Scholar 

  58. Fishell TA, Maheshwari A. Current applications for nicardipine in invasive and intervenional cardiology. J Invasive Cardiol 2004; 16(8): 428–32.

    Google Scholar 

  59. Liem A, Zijlstra F, Ottervanger JP, Hoorntje JC, Suryapranata H, de Boer MJ, Verheugt FW. High dose heparin as pretreatment for primary angioplasty in acute myocardial infarction: the Heparin in Early Patency (HEAP) randomized trial. J Am Coll Cardiol. 2000 Mar 1; 35(3): 600–4.

    Google Scholar 

  60. Chung WY, Han MJ, Cho YS, Kim KI, Chang HJ, Youn TJ, Chae IH, Choi DJ, Kim CH, Oh BH, Park YB, Choi YS.Effects of the early administration of heparin in patients with ST-elevation myocardial infarction treated by primary angioplasty. Circ J. 2007 Jun; 71(6): 862–7.

    Google Scholar 

  61. Ambrose JA, Almeida OD, Sharma SK, Torre SR, Marmur JD, Israel DH, Ratner DE, Weiss MB, Hjemdahl-Monsen CE, Myler RK, et al. Adjunctive thrombolytic therapy during angioplasty for ischemic rest angina. Results of the TAUSA Trial. TAUSA Investigators. Thrombolysis and Angioplasty in Unstable Angina trial. Circulation. 1994 Jul; 90(1): 69–77.

    Google Scholar 

  62. Kelly RV, Crouch E, Krumnacher H, Cohen MG, Stouffer GA. Safety of adjunctive intracoronary thrombolytic therapy during complex percutaneous coronary intervention: initial experience with intracoronary tenecteplase. Catheter Cardiovasc Interv. 2005 Nov; 66(3): 327–32.

    Article  PubMed  Google Scholar 

  63. Neumann FJ, Blasini R, Schmitt C, Alt E, Dirschinger J, Gawaz M, Kastrati A, Schomig A. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation. 1998 Dec 15; 98(24): 2695–701.

    Google Scholar 

  64. Giri S, Mitchel JF, Hirst JA, McKay RG, Azar RR, Mennett R, Waters DD, Kiernan FJ. Synergy between intracoronary stenting and abciximab in improving angiographic and clinical outcomes of primary angioplasty in acute myocardial infarction. Am J Cardiol. 2000 Aug 1; 86(3): 269–74.

    Google Scholar 

  65. Collet JP, Montalescot G, Lesty C, Mishal Z, Soria J, Choussat R, Drobinski G, Soria C, Pinton P, Barragan P, Thomas D. Effects of Abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention. Circulation. 2001 May 15; 103(19): 2328–31.

    Google Scholar 

  66. The ESPRIT investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet. 2000 Dec 16; 356(9247): 2037–44.

    Article  Google Scholar 

  67. Gibson CM, Cohen DJ, Cohen EA, Lui HK, Murphy SA, Marble SJ, Kitt M, Lorenz T, Tcheng JE. Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. Am J Cardiol 2001 Jun 1; 87(11): 1293–5.

    Google Scholar 

  68. Bartorelli AL, Trabattoni D, Galli S, Grancini L, Cozzi S, Ravagnani P. Successful dissolution of occlusive coronary thrombus with local administration of abciximab during PTCA Catheter Cardiovasc Interv 1999 Oct; 48(2): 211–3.

    Article  PubMed  CAS  Google Scholar 

  69. Wohrle J, Grebe OC, Nusser T et al. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation 2003 107(14): 1840–1843.

    Article  PubMed  Google Scholar 

  70. Pinto DS, Kirtane AJ, Ruocco NA, Deibele AJ, Shui A, Buros J, Murphy SA, Gibson CM. Administration of intracoronary eptifibatide during ST-elevation myocardial infarction. Am J Cardiol. 2005 Dec 1; 96(11): 1494–7.

    Google Scholar 

  71. Deibele AJ, Kirtane AJ, Pinto DS, Lucca MJ, Neva C, Shui A, Murphy SA, Tcheng JE, Gibson CM. Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina. J Thromb Thrombolysis. 2006 Aug; 22(1): 47–50.

    Article  PubMed  Google Scholar 

  72. Iancu AC, Lazar A. Successful management of the no-reflow syndome after venous graft stenting. J Invasive Cardiol. 2005 Dec; 17(12): E50–1.

    Google Scholar 

  73. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005 Nov 5; 366(9497): 1607–21.

    Google Scholar 

  74. Justicz AG, Farnsworth WV, Soberman MS, Tuvlin MB, Bonner GD, Hunter RL, Martino-Saltzman D, Sink JD, Austin GE.Reduction of myocardial infarct size by poloxamer 188 and mannitol in a canine model. Am Heart J. 1991 Sep; 122(3 Pt 1): 671–80.

    Article  PubMed  CAS  Google Scholar 

  75. O'Keefe JH, Grines CL, DeWood MA, Schaer GL, Browne K, Magorien RD, Kalbfleisch JM, Fletcher WO Jr, Bateman TM, Gibbons RJ. Poloxamer-188 as an adjunct to primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1996 Oct 1; 78(7): 747–50.

    Article  PubMed  Google Scholar 

  76. Schaer GL, Spaccavento LJ, Browne KF, Krueger KA, Krichbaum D, Phelan JM, Fletcher WO, Grines CL, Edwards S, Jolly MK, Gibbons RJ. Beneficial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarction. Results of a randomized, double-blind, placebo-controlled trial. Circulation. 1996 Aug 1; 94(3): 298–307.

    Google Scholar 

  77. CORE investigators. Effects of RheothRx on mortality, morbidity, left ventricular function, and infarct size in patients with acute myocardial infarction. Circulation. 1997 Jul 1; 96(1): 192–201.

    Google Scholar 

  78. Yasuda S, Townsend D, Michele DE, Favre EG, Day SM, Metzger JM. Dystrophic heart failure blocked by membrane sealant poloxamer. Nature. 2005 Aug 18; 436(7053): 1025–9.

    Google Scholar 

  79. Taira N. Similarity and dissimilarity in the mode and mechanism of action between nicorandil and classical nitrates: an overview. J Cardiovasc Pharmacol 1987; 10 Suppl 8: S1–9.

    PubMed  CAS  Google Scholar 

  80. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol 1989; 63: 18 J – 24 J.

    Article  Google Scholar 

  81. Ito H, Taniyama Y, Iwakura K, Nishikawa N, Masuyama T, Kuzuya T, Hori M, Higashino Y, Fujii K, Minamino T. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol. 1999 Mar; 33(3): 654–60.

    Google Scholar 

  82. Tsubokawa A, Ueda K, Sakamoto H, Iwase T, Tamaki S. Effect of intracoronary nicorandil administration on preventing no-reflow/slow flow phenomenon during rotational atherectomy.Circ J. 2002 Dec; 66(12): 1119–23.

    Article  PubMed  CAS  Google Scholar 

  83. Ono H, Osanai T, Ishizaka H, hanada H, Kamada T, Onodera H et al. Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention : role of inhibitory effect on reactive oxygen species formation.Am Heart J 2004; 148(4) E15.

    Article  PubMed  Google Scholar 

  84. Ishii H, Ichimiya S, Kanashiro M, Amano T, Imai K, Murohara T, Matsubara T Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction.Circulation. 2005 Aug 30; 112(9): 1284–8.

    Google Scholar 

  85. Ota S, Nishikawa H, Takeuchi M, Nakajima K, Nakamura T, Okamoto S, Setsuda M, Makino K, Yamakado T, Nakano T.Impact of nicorandil to prevent reperfusion injury in patients with acute myocardial infarction: Sigmart Multicenter Angioplasty Revascularization Trial (SMART).Circ J. 2006 Sep; 70(9): 1099–104.

    Article  PubMed  CAS  Google Scholar 

  86. Akao M, Ohler A, O'Rourke B, Marban E. Mitochondrial atp-sensitive potassium channels inhibit apoptosis induced by oxidative stress in cardiac cells. Circ Res 2001 Jun 22; 88(12): 1267–75.

    Article  PubMed  CAS  Google Scholar 

  87. Forbes RA, Steenbergen C, Murphy E. Diazoxide-induced cardioprotection requires signaling through a redox-sensitive mechanism. Circ Res 2001 Apr 27; 88(8): 802–9.

    Google Scholar 

  88. Karmazyn M. The role of the myocardial sodium–hydrogen exchanger in mediating ischemic and reperfusion injury. From amiloride to cariporide, Ann N Y Acad Sci 874 (1999), pp. 326–334.

    Article  PubMed  CAS  Google Scholar 

  89. Fantinelli JC, Cingolani HE, Mosca SM. Na+/H+ exchanger inhibition at the onset of reperfusion decreases myocardial infarct size: role of reactive oxygen species. Cardiovasc Pathol. 2006 Jul-Aug; 15(4): 179–84.

    Article  PubMed  CAS  Google Scholar 

  90. Theroux P, Chaitman BR, Danchin N, Erhardt L, Meinertz T, Schroeder JS, Tognoni G, White HD, Willerson JT, Jessel A. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) Investigators. Circulation. 2000 Dec 19; 102(25): 3032–8.

    Google Scholar 

  91. Klein HH, Pich S, Bohle RM, Lindert-Heimberg S, Nebendahl K. Na(+)/H(+) exchange inhibitor cariporide attenuates cell injury predominantly during ischemia and not at onset of reperfusion in porcine hearts with low residual blood flow. Circulation. 2000 Oct 17; 102(16): 1977–82.

    PubMed  CAS  Google Scholar 

  92. Rupprecht HJ, vom Dahl J, Terres W, Seyfarth KM, Richardt G, Schultheibeta HP, Buerke M, Sheehan FH, Drexler H. Cardioprotective effects of the Na(+)/H(+) exchange inhibitor cariporide in patients with acute anterior myocardial infarction undergoing direct PTCA. Circulation. 2000 Jun 27; 101(25): 2902–8.

    PubMed  CAS  Google Scholar 

  93. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000 Mar 17; 86(5): 580–8.

    PubMed  CAS  Google Scholar 

  94. Steg PG, Grollier G, Gallay P, Morice M, Karrillon GJ, Benamer H, Kempf C, Laperche T, Arnaud P, Sellier P, Bourguignon C, Harpey C. A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction. Int J Cardiol. 2001 Feb; 77(2–3): 263–73.

    Google Scholar 

  95. Flaherty JT, Pitt B, Gruber JW, Heuser RR, Rothbaum DA, Burwell LR, George BS, Kereiakes DJ, Deitchman D, Gustafson N, et al. Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction. Circulation. 1994 May; 89(5): 1982–91.

    PubMed  CAS  Google Scholar 

  96. Forman MB, Perry JM, Wilson BH, Verani MS, Kaplan PR, Shawl FA, Friesinger GC. Demonstration of myocardial reperfusion injury in humans: results of a pilot study utilizing acute coronary angioplasty with perfluorochemical in anterior myocardial infarction. J Am Coll Cardiol. 1991 Oct; 18(4): 911–8.

    Article  PubMed  CAS  Google Scholar 

  97. Wall TC, Califf RM, Blankenship J, Talley JD, Tannenbaum M, Schwaiger M, Gacioch G, Cohen MD, Sanz M, Leimberger JD, et al. Intravenous Fluosol in the treatment of acute myocardial infarction. Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial. TAMI 9 Research Group. Circulation. 1994 Jul; 90(1): 114–20.

    PubMed  CAS  Google Scholar 

  98. Santoro GM, Antoniucci D, Bolognese L, Valenti R, Buonamici P, Trapani M, Santini A, Fazzini PF. A randomized study of intravenous magnesium in acute myocardial infarction treated with direct coronary angioplasty. Am Heart J. 2000 Dec; 140(6): 891–7.

    Article  PubMed  CAS  Google Scholar 

  99. Gnaim CI and McGuire DK. Glucose-insulin-potassium therapy for acute myocardial infarction: What goes around comes around, American Heart Journal, Volume 148, Issue 6, December 2004, Pages 924–930.

    Article  PubMed  CAS  Google Scholar 

  100. J.F. LaDisa, J.G. Krolikowski, P.S. Pagel, D.C. Waltier and J.R. Kersten, Cardioprotection by glucose-insulin-potassium: dependence on KATP channel opening ad blood concentration before ischemia, Am J Physiol Heart Circ Physiol 287 (2004) (suppl), pp. H601–H607.

    Article  PubMed  CAS  Google Scholar 

  101. Bucciarelli-Ducci C, Bianchi M, De Luca L, Battagliese A, Di Russo C, Proietti P, Vizza CD, Fedele F. Effects of glucose-insulin-potassium infusion on myocardial perfusion and left ventricular remodeling in patients treated with primary angioplasty for ST-elevation acute myocardial infarction. Am J Cardiol. 2006 Nov 15; 98(10): 1349–53.

    Article  PubMed  CAS  Google Scholar 

  102. Fischell TA, Foster MT 3rd. Adenosine for reversal of "no reflow". Catheter Cardiovasc Interv. 1999 Apr; 46(4): 508.

    Article  PubMed  CAS  Google Scholar 

  103. Ishihara M, Sato H, Tateishi H, Kawagoe T, Shimatani Y, Kurisu S, Sakai K, Ueda K. Effects of various doses of intracoronary verapamil on coronary resistance vessels in humans. Jpn Circ J. 1997 Sep; 61(9): 755–61.

    Article  PubMed  CAS  Google Scholar 

  104. Oldenburg O, Eggebrecht H, Herrmann J, Naber CK, Haude M, Erbel R, Baumgart D. Dose-dependent effects of intracoronary verapamil on systemic and coronary hemodynamics. Cardiovasc Drugs Ther. 2000 Dec; 14(6): 651–5.

    Google Scholar 

  105. St John M, Heldman AW. Treatment of saphenous vein graft thrombosis with distal protection, thrombectomy, and adenosine prior to reperfusion: a complete approach to preserving microvascular integrity. J Invasive Cardiol. 2004 Jun; 16(6): 336–8.

    Google Scholar 

  106. Fischell TA, Carter AJ, Foster MT, Hempsall K, DeVries J, Kim DH, Kloostra A. Reversal of "no reflow" during vein graft stenting using high velocity boluses of intracoronary adenosine. Cathet Cardiovasc Diagn. 1998 Dec; 45(4): 360–5.

    Google Scholar 

  107. Wilensky RL, Pyles JM, Fineberg N. Increased thrombin activity correlates with increased ischemic event rate after percutaneous transluminal coronary angioplasty: lack of efficacy of locally delivered urokinase. Am Heart J. 1999 Aug; 138(2 Pt 1): 319–25.

    Article  PubMed  CAS  Google Scholar 

  108. Shin EK, Son JW, Sohn MS, Jin DK, Park GS, Koh KK, Ahn TH, Choi IS. Efficacy of heparin-coated stent in early setting of acute myocardial infarction. Catheter Cardiovasc Interv. 2001 Mar; 52(3): 306–12.

    Article  PubMed  CAS  Google Scholar 

  109. Grines CL, Cox DA, Stone GW, Garcia E, Mattos LA, Giambartolomei A, Brodie BR, Madonna O, Eijgelshoven M, Lansky AJ, O'Neill WW, Morice MC. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med. 1999 Dec 23; 341(26): 1949–56.

    Article  PubMed  CAS  Google Scholar 

  110. Pedro A. Lemos, Francesco Saia, Sjoerd H. Hofma, Joost Daemen, Andrew T. L. Ong, Chourmouzios A. Arampatzis, Angela Hoye, Eugene McFadden, Georgios Sianos, Pieter C. Smits, Willem J. van der Giessen, Pim de Feyter, Ron T. van Domburg, and Patrick W. Serruys. Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol, 2004; 43: 704–708.

    Article  Google Scholar 

  111. Chechi T, Vittori G, Biondi Zoccai GG, Vecchio S, Falchetti E, Spaziani G, Baldereschi G, Giglioli C, Valente S, Margheri M. Single-Center Randomized Evaluation of Paclitaxel-Eluting Versus Conventional Stent in Acute Myocardial Infarction (SELECTION). J Interv Cardiol. 2007 Aug; 20(4): 282–91.

    Article  PubMed  Google Scholar 

  112. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986 Nov; 74(5): 1124–36.

    PubMed  CAS  Google Scholar 

  113. Kuzuya T, Hoshida S, Yamashita N, Fuji H, Oe H, Hori M, Kamada T, Tada M. Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res. 1993; 72: 1293–1299.

    PubMed  CAS  Google Scholar 

  114. Kloner RA, Shook T, Przyklenk K, Davis VG, Junio L, Matthews RV, Burstein S, Gibson M, Poole WK, Cannon CP, et al. Previous angina alters in-hospital outcome in TIMI 4. A clinical correlate to preconditioning? Circulation. 1995 Jan 1; 91(1): 37–45.

    PubMed  CAS  Google Scholar 

  115. Bolli R. The late phase of preconditioning. Circ Res 2000 Nov 24; 87(11): 972–83.

    PubMed  CAS  Google Scholar 

  116. Forbes RA, Steenbergen C, Murphy E. Diazoxide-induced cardioprotection requires signaling through a redox-sensitive mechanism. Circ Res 2001 Apr 27;88(8): 802–9.

    Article  PubMed  CAS  Google Scholar 

  117. Sasaki N, Sato T, Ohler A, O'Rourke B, Marban E. Activation of mitochondrial ATP-dependent potassium channels by nitric oxide. Circulation 2000 Feb 1; 101(4): 439–45.

    Google Scholar 

  118. Sato T, Sasaki N, O'Rourke B, Marban E. Adenosine primes the opening of mitochondrial ATP-sensitive potassium channels: a key step in ischemic preconditioning? Circulation 2000 Aug 15; 102(7): 800–5.

    Google Scholar 

  119. Miura T, Liu Y, Kita H, Ogawa T, Shimamoto K. Roles of mitochondrial ATP-sensitive K channels and PKC in anti-infarct tolerance afforded by adenosine A1 receptor activation. J Am Coll Cardiol 2000 Jan; 35(1): 238–45.

    Google Scholar 

  120. Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L'Huillier I, Aupetit JF, Bonnefoy E, Finet G, André-Fouët X, Ovize M. Postconditioning the human heart. Circulation. 2005 Oct 4; 112(14): 2143–8.

    Google Scholar 

  121. Limbruno U, Petronio AS, Amoroso G, Baglini R, Paterni G, Merelli A, Mariotti R, Raffaele De Caterina, Mariani M. The impact of coronary artery disease on the coronary vasomotor response to nonionic contrast media. Circulation. 2000 Feb 8; 101(5): 491–7.

    PubMed  CAS  Google Scholar 

  122. Chronos NA, Goodall AH, Wilson DJ, Sigwart U, Buller NP. Profound platelet degranulation is an important side effect of some types of contrast media used in interventional cardiology. Circulation. 1993 Nov; 88(5 Pt 1): 2035–44.

    PubMed  CAS  Google Scholar 

  123. Falck G, Bruvold M, Schjott J, Jynge P. Protective effects of repetitive injections of radiographic contrast media on the subsequent tolerance to ischemia in the isolated rat heart. Cardiovasc Intervent Radiol 2000 Nov-Dec; 23(6): 466–71.

    Article  PubMed  CAS  Google Scholar 

  124. Gibson CM, Kirtane AJ, Murphy SA, Marble SJ, de Lemos JA, Antman EM, Braunwald E. Impact of contrast agent type (ionic versus nonionic) used for coronary angiography on angiographic, electrocardiographic, and clinical outcomes following thrombolytic administration in acute myocardial infarction. Catheter Cardiovasc Interv. 2001 May; 53(1): 6–11.

    Article  PubMed  CAS  Google Scholar 

  125. Davidson CJ, Laskey WK, Hermiller JB, Harrison JK, Matthai W Jr, Vlietstra RE, Brinker JA, Kereiakes DJ, Muhlestein JB, Lansky A, Popma JJ, Buchbinder M, Hirshfeld JW Jr. Randomized trial of contrast media utilization in high-risk PTCA: the COURT trial. Circulation. 2000 May 9; 101(18): 2172–7.

    PubMed  CAS  Google Scholar 

  126. Gibson CM, Buros J, Ciaglo LN, Southard MC, Takao S, Harrigan C, Filopei J, Lew M, Marble SJ, Murphy SA, Cohen MG. Impact of iodinated contrast injections on percent diameter coronary arterial stenosis and implications for trials of intracoronary pharmacotherapies in patients with ST-elevation myocardial infarction. Am J Cardiol. 2007 Jul 1; 100(1): 13–17.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiovascular Division, University of Miami, Miller School of Medicine, Miami, FL 33136

    Alan W. Heldman

Authors
  1. Yeraldine Toledo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan W. Heldman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alan W. Heldman .

Editor information

Editors and Affiliations

    Rights and permissions

    Reprints and permissions

    Copyright information

    © 2009 Humana Press, a part of Springer Science+Business Media, LLC

    About this chapter

    Cite this chapter

    Toledo, Y., Heldman, A.W. (2009). Therapies Targeted at Preserving Microvascular Integrity and Preventing Reperfusion Injury. In: Tcheng, J. (eds) Primary Angioplasty in Acute Myocardial Infarction. Contemporary Cardiology. Humana Press. https://doi.org/10.1007/978-1-60327-497-5_9

    Download citation

    • DOI: https://doi.org/10.1007/978-1-60327-497-5_9

    • Published:

    • Publisher Name: Humana Press

    • Print ISBN: 978-1-60327-496-8

    • Online ISBN: 978-1-60327-497-5

    • eBook Packages: MedicineMedicine (R0)

    Publish with us

    Policies and ethics

    Search

    Navigation